Looking for Scientific Founders? Click here.
George Trainor, PhD
Dr. Trainor has advanced over 35 drug candidates into clinical development in a diverse spectrum of therapeutic areas including antivirals, cancer, neuroscience, and inflammation. He joined BioMotiv after leaving Bristol Myers Squibb Company as Vice President – Oncology and Early Discovery Chemistry. Prior to being merged into Bristol Myers Squibb, Dr. Trainor was Executive Director for Medicinal Chemistry at Dupont/Dupont Merck Pharmaceuticals. In 2011, Trainor won the American Chemical Society’s “Heroes of Chemistry Award” for his work on DNA sequencing and has served on Grant Review Study Sections for the NIH and DOE. Dr. Trainor did his undergraduate work at Stevens Institute of Technology, received his PhD in Organic Chemistry at Harvard University, and was an NIH Postdoctoral Fellow at Columbia University.
Juliana M. Woda, PhD
Dr. Woda has over 23 years of biological research and drug development experience. Prior to BioMotiv, she worked as Director of Translational Research for Juventas Therapeutics in Cleveland, overseeing all aspects of preclinical development of novel biologics. Dr. Woda also spent four years at Athersys (Cleveland) as a Scientist and later Senior Scientist in Regenerative Medicine, developing cell therapy for the treatment of cardiovascular, immunological, and neurological indications. She completed her PhD in Biological and Biomedical Sciences at Harvard University, specializing in Cell and Developmental Biology. Her postdoctoral fellowship with Massachusetts General Hospital focused on examining the normal function of the protein mutated in Huntington’s Disease. Dr. Woda holds an undergraduate degree from Rutgers University.